Advertisement
 

doctorslounge.com

 
Powered by
Careerbuilder

 

                    Home  |  Forums  |  Humor  |  Advertising  |  Contact
   Ask a Doctor

   News via RSS

   Newsletter

   Oncology

   News

 

 Conferences


   CME

   Forum Archives

   Diseases

   Symptoms

   Labs

   Procedures

   Drugs

   Links
   Specialties

   Cardiology

   Dermatology

   Endocrinology

   Fertility

   Gastroenterology

   Gynecology

   Hematology

   Infections

   Nephrology

   Neurology

   Oncology

   Orthopedics

   Pediatrics

   Pharmacy

   Primary Care

   Psychiatry

   Pulmonology

   Rheumatology

   Surgery

   Urology

   Other Sections

   Membership

   Research Tools

   Medical Tutorials

   Medical Software

 

 Headlines:

 
 

Back to index

Cancer Chemotherapy Regimen for Breast Cancer


 AVM                                                    breast(15)
 _________________________________________________________________
  adriamycin...... 30 mg/sqm IV day 1 and 28.
  vinblastine..... 6 mg/sqm IV day 1 and 18.
  mitomycin....... 10 mg/sqm IV day 1.
  FREQUENCY....... Repeat cycle every 8 weeks.


  reference...
    Luikart SD.  Witman GB.  Portlock CS. Adriamycin 
    (doxorubicin), vinblastine, and mitomycin C combination 
    chemotherapy in refractory breast carcinoma. Cancer.  
    54(7):1252-5, 1984 Oct 1. 
  abstract...
    Twenty-seven evaluable patients with refractory, metastatic 
    breast carcinoma were treated with Adriamycin (doxorubicin) 30 
    mg/m2 and vinblastine 6 mg/m2 intravenously on days 1 and 28 
    every 8 weeks, and mitomycin C 10 mg/m2 intravenously on day 1 
    every 8 weeks (AVM). There were three complete and six partial 
    responses for a total response rate of 33%. In addition, 2 
    patients had minimal responses, and 10 patients achieved 
    disease stabilization. Median time to disease progression for 
    responders was 116 days (range, 49-812+ days). Drug toxicity 
    was tolerable: 12 patients (44%) experienced significant bone 
    marrow suppression. There were no drug-related deaths. 
    Although AVM appears to be an active drug combination in 
    heavily pretreated patients with metastatic breast carcinoma, 
    the contribution of vinblastine and mitomycin C to single 
    agent Adriamycin in previously treated patients is not clear 
    from this study. 
advertisement.gif (61x7 -- 0 bytes)
 

Are you a doctor or a nurse?

Do you want to join the Doctors Lounge online medical community?

Participate in editorial activities (publish, peer review, edit) and give a helping hand to the largest online community of patients.

Click on the link below to see the requirements:

Doctors Lounge Membership Application



 

 advertisement.gif (61x7 -- 0 bytes)

 

 

 



We subscribe to the HONcode principles of the HON Foundation. Click to verify.
We subscribe to the HONcode principles. Verify here

Privacy Statement | Terms & Conditions | Editorial Board | About us
Copyright 2001-2012 DoctorsLounge. All rights reserved.